

FOI REF: 22/440

22nd August 2022

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- **Nivolumab (monotherapy)**
- **Nivolumab AND Ipilimumab (combination)**

East Sussex Healthcare NHS Trust does not provide this service. Patients' being treated for Melanoma are referred to University Hospitals Sussex NHS Foundation Trust (UHS) for treatment. Would you therefore please forward this part of your request direct to UHS via the following email address:

UHSussex.foi@nhs.net

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma?

- | | |
|-----------------------------------|---|
| • Nivolumab (monotherapy) | 1 |
| • Nivolumab + Ipilimumab | 0 |
| • Nivolumab + Cabozantinib | 0 |
| • Avelumab + Axitinib | 1 |

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Cont.../

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)?

- Nivolumab 1
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q4. Does your trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.

Please refer to question 1.

Q5. Does your trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.

The Trust do not have any open clinical trials for the treatment of Renal Cell carcinoma.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net